EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells

Isadora Oliveira Ansaloni Pereira, Glenda Nicioli da Silva iD, Tamires Cunha Almeida, Ana Paula Braga Lima iD, André Luiz Ventura Sávio, Katia Ramos Moreira Leite iD, Daisy Maria Fávero Salvadori

Molecules · 2023

DOI: 10.3390/molecules28052412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Isadora Oliveira Ansaloni Pereira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Análises Clínicas, Pharmacy School, UFOP-Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long non-coding RNAs are frequently found to be dysregulated and are linked to carcinogenesis, aggressiveness, and chemoresistance in a variety of tumors. As expression levels of the JHDM1D gene and lncRNA JHDM1D-AS1 are altered in bladder tumors, we sought to use their combined expression to distinguish between low-and high-grade bladder tumors by RTq-PCR. In addition, we evaluated the functional role of JHDM1D-AS1 and its association with the modulation of gemcitabine sensitivity in high-grade bladder-tumor cells. J82 and UM-UC-3 cells were treated with siRNA-JHDM1D-AS1 and/or three concentrations of gemcitabine (0.39, 0.78, and 1.56 µM), and then submitted to cytotoxicity testing (XTT), clonogenic survival, cell cycle progression, cell morphology, and cell migration assays. When JHDM1D and JHDM1D-AS1 expression levels were used in combination, our findings indicated favorable prognostic value. Furthermore, the combined treatment resulted in greater cytotoxicity, a decrease in clone formation, G0/G1 cell cycle arrest, morphological alterations, and a reduction in cell migration capacity in both lineages compared to the treatments alone. Thus, silencing of JHDM1D-AS1 reduced the growth and proliferation of high-grade bladder-tumor cells and increased their sensitivity to gemcitabine treatment. In addition, the expression of JHDM1D/JHDM1D-AS1 indicated potential prognostic value in the progression of bladder tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingUrinary Bladder NeoplasmsHumansGemcitabineUrinary BladderCell Line, TumorBiomarkersCell MovementCell ProliferationGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

JHDM1D-AS1bladder cancerlong non-coding RNAs

Substanzen

RNA, Long NoncodingGemcitabineBiomarkers

Autor:innen und Institutionen

  • Departamento de Análises Clínicas, Pharmacy School, UFOP-Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.
  • Laboratory of Pain and Signaling, Butantan Institute, Sao Paulo 05503-900, SP, Brazil.
  • Departamento de Odontologia, Faculdade do Centro Oeste Paulista-FACOP, Piratininga 17490-000, SP, Brazil.
  • Departamento de Ciências Médicas, Universidade do Oeste Paulista-UNOESTE, Jaú 19050-900, SP, Brazil.
  • Departamento de Cirurgia, Medical School, USP-University of São Paulo, São Paulo 05508-060, SP, Brazil.
  • Departamento de Patologia, Medical School, UNESP-São Paulo State University, Botucatu 01151-000, SP, Brazil.

ORCID-Profile: Glenda Nicioli da Silva, Ana Paula Braga Lima, Katia Ramos Moreira Leite

Förderung

  • National Council for Scientific and Technological Development
  • Coordenação de Aperfeicoamento de Pessoal de Nível Superior
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Universidade Federal de Ouro Preto
  • CAPES—Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • CNPq—Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Pereira, I. O. A., da Silva, G. N., Almeida, T. C., Lima, A. P. B., Sávio, A. L. V., Leite, K. R. M., & Salvadori, D. M. F. (2023). LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells. Molecules. https://doi.org/10.3390/molecules28052412

Vancouver

Pereira IOA, da Silva GN, Almeida TC, Lima APB, Sávio ALV, Leite KRM, et al. LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells. Molecules. 2023. doi:10.3390/molecules28052412

BibTeX
@article{Pereira2023,
  author = {Pereira, Isadora Oliveira Ansaloni and da Silva, Glenda Nicioli and Almeida, Tamires Cunha and Lima, Ana Paula Braga and Sávio, André Luiz Ventura and Leite, Katia Ramos Moreira and Salvadori, Daisy Maria Fávero},
  title = {LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28052412}
}
Kostenlos starten →